BHVN

Biohaven Ltd. Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Biohaven Ltd. is a biopharmaceutical company focused on immunology, obesity, neuroscience, and oncology. The company is currently pre-revenue, advancing a portfolio of therapeutics including Kv7 ion channel modulators, MoDE/TRAP degraders, and myostatin-activin pathway agents. In Q4 2025, the company initiated strategic portfolio and cost-optimization measures to prioritize three key late-stage clinical programs.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by $91.1 million (41%) compared to Q1 2025. This was driven by a strategic reprioritization of programs in Q4 2025, resulting in lower direct R&D spend and preclinical costs.
• Share-Based Compensation: Non-cash share-based compensation expense dropped significantly to $28.3 million from $53.1 million in the prior year, attributed to lower grant date fair values for equity awards issued in Q1 2026.
• Liquidity Improvement: Cash and cash equivalents increased by approximately $174.7 million year-over-year, bolstered by $178.9 million in net proceeds from the issuance of common shares under the Equity Distribution Agreement.
• One-Time Payments: Operating cash outflows included a $42.7 million cash payment to Knopp Biosciences in Q1 2026 related to the settlement of the "2025 Additional Consideration True-Up."

Outlook, Risks, and Management Commentary

• Clinical Milestones:
  • BHV-1300 (Graves' Disease): First-in-patient data showed complete suppression of disease-causing antibodies. A pivotal trial is planned for mid-2026.
  • BHV-1400 (IgA Nephropathy): Early patient data showed resolution of hematuria and proteinuria. A pivotal study design was aligned with the FDA in Q4 2025, with initiation expected mid-2026.
  • Opakalim (Epilepsy): Topline results from the RISE 3 Phase 2/3 trial are expected in the second half of 2026.
  • Taldefgrobep Alfa (Obesity): Enrollment in the Phase 2 proof-of-concept study was completed in March 2026; topline results expected in H2 2026.
• Capital Resources: Management expects existing cash, cash equivalents, and marketable securities to fund operations for at least one year from the filing date. Future funding will likely require additional equity or debt financings.
• Debt Covenants: The company holds $250 million in senior secured notes (First Notes). A covenant requires audited financial statements to be free of "going concern" qualifications. Failure to meet this could trigger an event of default and acceleration of payments.
• Legal Proceedings: A shareholder class-action lawsuit was filed in July 2025 (amended March 2026) alleging securities law violations regarding disclosures on troriluzole and opakalim. The company intends to file a motion to dismiss.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $150M quarterly operating cash burn against the $347.8M liquidity position.
• Debt Covenant Compliance: Confirm the status of the "going concern" audit qualification for the 2025 fiscal year to ensure no default on the $250M Note Purchase Agreement.
• Equity Dilution: Assess the impact of the $178.9M raised via the Equity Distribution Agreement on shareholder dilution and remaining capacity under the agreement ($118.7M available).
• Clinical Execution: Monitor the initiation of pivotal trials for BHV-1300 and BHV-1400 in mid-2026 as critical value drivers.
• Legal Exposure: Track the progress of the shareholder lawsuit and potential settlement or dismissal outcomes.